COGNITION THERAPEUTICS INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Cognition Therapeutics reported Q2 2026 net loss of $3.9M (vs. $6.7M in Q2 2025) with cash of $34.8M plus $21.6M in NIH grant funds remaining, funding operations into Q4 2027. The company received FDA alignment on Phase 3 trial design for zervimesine in DLB psychosis (planned mid-2027 initiation), a patent allowance extending protection through 2045, and extended expanded access program funding from a second philanthropic donor. R&D expenses decreased to $5.1M from $11.5M YoY due to lower trial activities.
Why this rating
Positive clinical/regulatory progress and improved burn rate extend runway. At $18.2M market cap, $34.8M cash is substantial but Phase 3 initiation risk remains material. Routine quarterly update with incremental momentum.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.